Joseph Aloi, MD, shares details about this presentation, which begins Monday, June 28, at 9:36 a.m. ET.
Rajesh Garg, MD, shares details about this presentation, which begins Monday, June 28, at 12:20 p.m. ET.
Guoxun Chen, PhD, shares details about this presentation, which begins Monday, June 28, at 4:30 p.m. ET.
Lorenzo Pasquali, MD, PhD, shares details about this presentation, which begins Tuesday, June 29, at 9:00 a.m. ET.
Marcus D. Goncalves, MD, PhD, shares details about this presentation, which begins Tuesday, June 29, at 9:30 a.m. ET.
Amir Moheet, MBBS, shares details about this presentation, which begins Friday, June 25, at 1:15 p.m. ET.
A combined SGLT1/SGLT2 inhibitor may be the next addition to the armamentarium of drugs for patients with diabetes. Deepak Bhatt, MD, MPH, will explain why and take a comprehensive look at data from recent clinical trials of sotagliflozin.
Hertzel C. Gerstein, MD, MSc, FRCPC, will offer insight into the use of an exendin-based GLP-1 receptor agonist in people with type 2 diabetes and high cardiovascular risk.
Richard I.G. Holt, PhD, FRCP, and Anne L. Peters, MD, and their writing team will summarize the key topics addressed by this trans-Atlantic collaboration.
Veterans and active-duty military personnel with diabetes can now receive self-management education in a simulated environment.